Navigation Links
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
Date:7/9/2014

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. CRS3123 (previously known as REP3123) is a narrow-spectrum agent that inhibits C. difficile growth while sparing normal intestinal bacteria.

The Phase I trial will enroll up to 30 healthy men and women ages 18 to 45 in a dose-escalation study to evaluate the investigational drug's safety and tolerability. Quintiles, through Dynport Vaccine Company, is conducting the study of CRS3123. The medication is being provided by its developer, Crestone, Inc., a pharmaceutical company based in Boulder, Colo.

C. difficile infection affects the digestive track with manifestations ranging from mild diarrhea to life-threatening colitis. Infection most commonly affects patients in hospitals or long-term care facilities and people who have taken antibiotics. Each year, roughly 250,000 people in the United States require hospital care for C. difficile infection and at least 14,000 people die from the infection, according to the U.S. Centers for Disease Control and Prevention (CDC). As a result, the CDC identified C. difficile as an urgent public health threat in its 2013 report on antibiotic resistance. Resistance to the antibiotics currently used to treat C. difficile is not yet a problem, but the bacteria spreads rapidly because it is naturally resistant to many drugs used to treat other infections. Recurrent infections pose a particular clinical challenge, especially those caused by a newer, stronger C. difficile strain, which result in up to 25 percent of patients needing additional therapy.

In the new clinical trial, participants will be randomly assigned into three groups of 10 participants each (8 participants will receive the inves
'/>"/>

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. Mayo Clinic launches whole genome breast cancer study
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. UCLA launches first face transplantation program in western US
5. Georgia Tech launches HomeLab to help companies evaluate home health technologies
6. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
7. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
8. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
9. 'Music Makes It Better' Campaign Launches with Justin Bieber, Victoria Justice, and The Band Perry
10. Fieldtex Products Launches a New Wellness Rewards Service for Companies
11. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
(Date:3/4/2015)... Nike Swim Camps offer outstanding coaching by ... to stimulate a love of swimming in a positive ... the opportunity to train with some of the most ... President of US Sports Camps. “Our program directors provide ... confidence and improve their technique.” , Nike Swim Camp ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... therapeutics market is driven by the increasing incidence of ... encouraging pipeline of late stage drugs. The unmet medical ... fore the untapped potential in the market. Presently, there ... drugs that overcome the limitations of current generation drugs. ...
(Date:3/4/2015)... Ohio (PRWEB) March 04, 2015 Nitrosigine®, ... an ingredient in premium sports nutrition products, is hosting ... Trainer booth in the Terrace Ballroom at The Arnold ... from March 5, 2015 to March 8, 2015. ... silicate with FDA New Dietary Ingredient notification status; now ...
(Date:3/4/2015)... 2015 Follow us on LinkedIn ... the appearance of the skin and body, are witnessing ... therapeutic agents to achieve the desired product properties and ... obsessed with physical beauty, youth, and achievement. Demand for ... sales of cosmetics. Growth in the market is driven ...
(Date:3/4/2015)... The report “Vasculitis – Pipeline Review, ... for Vasculitis. Vasculitis is a disease that features tenderness ... diseases is not known. Vasculitis can affect any body ... Symptoms can include fever, weight loss, tiredness, aches, pains, ... a limb. Vasculitis is treatable, but it is not ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Swim Camps Announce the 2015 Swim Camps Lineup 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4
... University of Utah researchers in the development and testing of ... would transmit the nerve impulses from nerves in the residual ... then to the bionic arm. This will facilitate the person ... ,Sensors placed in the artificial arm will be designed ...
... ocean currents in climate change and the story behind Antarctica’s ... to be holding the clue. ,An element pretty ... teeth has offered a clue to the University of Florida ... Atlantic and Pacific might have opened up. This has happened ...
... Administration is being prompted by the Drug Manufacturer, Wyeth ... hormone drugs to treat menopause.// The drugs are made ... approved. ,Following Wyeth's recommendation to the FDA, the ... on these custom-made treatments, and have requested the agency ...
... Functional and structural difference in the brain can explain ... in unique ways to the effects// of certain pain-relief ... Georgia State University and the Atlanta-based Center for Behavioral ... conducted on rat brains, the results highlight that similar ...
... a report by the Food and Agriculture Organisation (FAO) of ... animal species said that domestic and wild birds spread the ... accumulated since the start of the avian influenza crisis (the ... in the transmission of the virus in the natural setting. ...
... and as a clean up drive legalisation of drugs is ... free drugs to addicts// to help clean up the Downtown ... Sam Sullivan a donation by an anonymous donor of $500,000 ... ,The reason and goal behind this whole exercise would be ...
Cached Medicine News:Health News:Gender Difference In Pain Experience Explained By Brain Diversity 2
(Date:3/4/2015)... 4, 2015   Symbiomix Therapeutics , a ... for serious women,s health infections, today announced results ... its lead product candidate, SYM-1219, was safe and ... that contraceptive efficacy for birth control pills would ... These results will be presented on March 6 ...
(Date:3/3/2015)... 2015  The packaging industry plays a major ... provides containment and drug safety but also ensures ... patent loss delivers more generics into the market, ... turn encouraging low-cost innovation in emerging markets. The ... the pharmaceutical packaging industry towards low-cost, sustainable and ...
(Date:3/3/2015)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical solutions ... at the 27 th Annual ROTH Conference, which is ... California from March 8 to March 11. ... , will be presenting on Monday, March 9 at 12:00 ... , the company,s Vice President of Finance and Chief Accounting ...
Breaking Medicine Technology:Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5Customization is the New Formula in Global Pharmaceutical Packaging, Finds Frost & Sullivan 2Customization is the New Formula in Global Pharmaceutical Packaging, Finds Frost & Sullivan 3Customization is the New Formula in Global Pharmaceutical Packaging, Finds Frost & Sullivan 4Vermillion To Present at 27th Annual ROTH Conference on March 9 2
... 8, 2010 George Products Company, Inc. has announced ... of its OASIS Inspection Systems. Florida ... southeast Florida. OASIS Inspection Systems is a line of ... to quality control departments across the United States. Tim ...
... 1st to the 3rd of March 2011, vaccine leaders ... World Summit in New Delhi. The event will be ... Vaccine Manufacturers Network). Participants will be discussing ... pandemic surveillance programs, low cost and fast vaccine manufacturing ...
Cached Medicine Technology:Florida Metrology To Distribute OASIS Inspection Systems 2World Vaccine Leaders to Meet in New Delhi India to Tackle Global Public Health Challenges 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: